Unicycive Therapeutics UNCY 深 滬
等待開盤 10-29 09:30:00 美东时间
3.76
+0.150
+4.16%
華盛通- 最 高3.78
- 今 開3.60
- 成交量 113.36万股
- 最 低 3.575
- 昨 收 3.61
- 總市值 1.05亿
- 52周最高 8.74
- 市盈率 靜 --
- 換手率 4.07%
- 52周最低 3.35
- 委 比 -36.31%
- 總股本 2785.53万
- 歷史最高 87.30
- 量 比 0.93
- 振 幅 5.68%
- 歷史最低 2.02
- 每 手 1
- 風險率 1.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Unicycive Therapeutics收跌7.97%，成交额485.04万美元
10月27日，Unicycive Therapeutics（UNCY）收跌7.97%，报3.58美元，成交额485.04万美元，市值9972.2万美元。 行情数...
10-27 07:03
Unicycive Therapeutics Receives FDA Acceptance Of Its NDA Resubmission For Oxylanthanum Carbonate For Treatment Of Hyperphosphatemia In Patients With Chronic Kidney Disease On Dialysis
Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) f...
10-21 19:09
Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate New Drug Application Resubmission and PDUFA Date of March 25, 2027
Unicycive Therapeutics announced the FDA acceptance of its resubmitted NDA for oxylanthanum carbonate (OLC), an investigational oral phosphate binder for treating hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. The resubmission followed a June 2026 Complete Response Letter (CRL) and includes Chemistry, Manufacturing, and Controls (CMC) data from a new third-party manufacturing vendor. The FDA has assigned a PDUFA target ac...
10-21 11:05
Unicycive Therapeutics收跌6.41%，成交额370.97万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 07:09
美股大行评级 | 潜在涨幅11184.05%！如瑞迪博士获花旗上调目标价至1450美元，维持"买入"评级
今日重点评级关注：花旗：上调如瑞迪博士"买入"评级，目标价从1040美元升至1450美元；加拿大帝国商业银行：维持Inventiva"买入"评级，目标价从20美元升至21美元
09-30 08:33
Unicycive Therapeutics Discloses Securities Class Action Filed September 3 Against Company And Certain Officers
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001766140/000121390026104076/ea0306890-8k_unicycive.htm
09-29 04:37
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Benchmark Maintains Speculative Buy on Unicycive Therapeutics, Raises Price Target to $15
Benchmark analyst Bruce Jackson maintains Unicycive Therapeutics (NASDAQ:UNCY) with a Speculative Buy and raises the price target from $13 to $15.
08-20 23:38
美股大行评级 | 潜在涨幅544.53%！Scynexis获古根海姆升目标价至33美元，维持"买入"评级
今日重点评级关注：古根海姆：维持Scynexis"买入"评级，目标价从24美元升至33美元；韦德布什：维持Kura Oncology"跑赢大市"评级，目标价从36美元升至38美元
08-14 11:51
B. Riley Securities Reiterates Buy on Unicycive Therapeutics, Lowers Price Target to $20
B. Riley Securities analyst Mayank Mamtani reiterates Unicycive Therapeutics (NASDAQ:UNCY) with a Buy and lowers the price target from $22 to $20.
08-13 21:56
